Cardiovascular Disease Doctors in Upland, PA Accepting Medicare

5 Cardiovascular Disease doctors found. Showing 1 - 5

Joel Krackow, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Blvd, Pob Ii Suite 224, Upland, PA 19013 Phone: 610-876-2400    Fax: 610-876-4308

Roselle Mesmer, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Blvd - Bldg 1 Ste 400, Upland, PA 19013 Phone: 610-876-2400    Fax: 610-876-4308

Dr. Michael Andrew Lashner, D.O. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Blvd, Bldg 1 - Suite 400, Upland, PA 19013 Phone: 610-876-2400

Dr. Andrew Joseph Mehalick, D.O. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Blvd, Bldg 1 - Suite 400, Upland, PA 19013 Phone: 610-876-2400    Fax: 610-876-2400

Michael Adesman, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Boulevard, Building #1 Suite 400, Upland, PA 19013 Phone: 610-876-2400    Fax: 610-876-4308

News Archive

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies - one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

Taking health technology to the top

At the Innovations in Health and Community Care Forum at Old Parliament House on Thursday 3 March, leading health academics and professionals presented compelling arguments supporting the need for integrating assistive technology into health and community models of care.

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Elan Corporation, plc (NYSE: ELN) announced today the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of 2 doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures.

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

Derycz Scientific first quarter total revenue increases 64% to $9.9 million

Derycz Scientific, Inc., a leader in information logistics solutions and a pioneer in facilitating the flow of information from content publishers to enterprise customers in Life Sciences and other research intensive industries, today reported financial and operating results for the first quarter of its fiscal year 2012.

Read more Medical News

› Verified 9 days ago